Nott D M, Baxter J Y, Grime J S, Day D W, Cooke T G, Jenkins S A
University Department of Surgery, Royal Liverpool Hospital, UK.
Br J Surg. 1989 Nov;76(11):1149-51. doi: 10.1002/bjs.1800761113.
Administration of a long active analogue of somatostatin, SMS 201-995 (2 micrograms subcutaneously twice a day) for 3 weeks after intraportal administration of Walker cells significantly inhibited their growth and development in the liver. This was not due to a direct cytotoxic effect of the analogue on Walker cells whose growth was stimulated in vitro. Furthermore, SMS 201-995 had no effect on the growth of Walker cells implanted into the thigh of rats suggesting that the inhibitory action of the analogue could be confined to tumour cells growing in the liver. Further studies suggested that the inhibitory effect of SMS 201-995 on the growth of Walker cells in the liver could be related to a marked stimulation of the hepatic reticuloendothelial system, by a reduction in portal venous flow in the early stages of treatment or by a combination of these effects. Further studies are required to delineate more precisely the mechanism whereby SMS 201-995 inhibits the growth of hepatic tumour derived from intraportal administration of Walker cells.
在经门静脉注射Walker细胞后，给予长效生长抑素类似物SMS 201-995（每天皮下注射2微克，共3周），可显著抑制其在肝脏中的生长和发育。这并非由于该类似物对Walker细胞有直接细胞毒性作用，因为Walker细胞在体外生长是受刺激的。此外，SMS 201-995对植入大鼠大腿的Walker细胞生长没有影响，这表明该类似物的抑制作用可能仅限于在肝脏中生长的肿瘤细胞。进一步研究表明，SMS 201-995对肝脏中Walker细胞生长的抑制作用可能与显著刺激肝网状内皮系统有关，也可能与治疗早期门静脉血流减少有关，或者是这些作用的综合结果。需要进一步研究以更精确地阐明SMS 201-995抑制经门静脉注射Walker细胞后产生的肝肿瘤生长的机制。
